Extension Study for the Port Delivery System With Ranibizumab (Portal)
NCT ID: NCT03683251
Last Updated: 2026-02-02
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE3
1000 participants
INTERVENTIONAL
2018-09-20
2029-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Phase III Study to Evaluate the Port Delivery System With Ranibizumab Compared With Monthly Ranibizumab Injections in Participants With Wet Age-Related Macular Degeneration
NCT03677934
A Study of 36-Week Refill Exchanges of Port Delivery System (PDS) With Ranibizumab in nAMD
NCT06847542
A Study Assessing Corneal Endothelial Cells in Participants With Neovascular Age-related Macular Degeneration (nAMD) Treated With the Port Delivery System With Ranibizumab (PDS)
NCT04853251
Study of the Efficacy and Safety of the Ranibizumab Port Delivery System for Sustained Delivery of Ranibizumab in Patients With Subfoveal Neovascular Age-Related Macular Degeneration
NCT02510794
A Study Of The Effectiveness And Safety Of A 36-Week Refill Regimen For The Port Delivery System With Ranibizumab Vs Aflibercept Treat & Extend In Subjects With Neovascular Age-Related Macular Degeneration
NCT05126966
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The Re-implantation sub-study (sub-study 2) will evaluate the safety of re-implantation with the updated PDS with ranibizumab . Up to 100 participants who previously participated in the main study in the United States will be enrolled and followed for a maximum of 72 weeks post-re-implantation in the substudy.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
PDS Implant Cohort 3 (US only)
Participants in the intravitreal ranibizumab arm of Study GX28228 who will receive the PDS implant upon study entry and refill-exchanges of 100 mg/mL ranibizumab Q24W. Participants will switch to an every 12 weeks (Q12W) visit schedule from Week 168 to Week 240.
Eligible participants from Study GX28228 will be enrolled upon completion of their final visit.
PDS Implant with Ranibizumab 100 mg/mL
Will be administered as per the schedule described in individual arm
PDS Implant Cohort 4 (US only)
Participants in the intravitreal ranibizumab arm of Study GR40548 who will receive the PDS implant upon study entry and refill-exchanges of 100 mg/mL ranibizumab Q24W. Participants will switch to an every 12 weeks (Q12W) visit schedule from Week 144 to Week 240.
Eligible participants from Study GR40548 will be enrolled upon completion of their final visit.
PDS Implant with Ranibizumab 100 mg/mL
Will be administered as per the schedule described in individual arm
PDS Implant Cohort 5 (ex-US only)
Participants from Study WR42221 who completed Week 24 but were not eligible to be randomized within WR42221 and who will be treated with refill-exchanges of ranibizumab 100 mg/mL Q24W. Participants will be in the study for a minimum of 144 weeks and may continue after Week 144 until the PDS has received Health Authority approval (or non-approval) in their respective country and/or until the decision to close the study has been made by the sponsor.
PDS Implant with Ranibizumab 100 mg/mL
Will be administered as per the schedule described in individual arm
PDS Implant Cohort 6 (ex-US only)
Participants from Study WR42221 randomized to the Q24W arm, who will continue to be treated with refill-exchanges of ranibizumab 100 mg/mL Q24W. Participants will be in the study for a minimum of 144 weeks and may continue after Week 144 until the PDS has received Health Authority approval (or non-approval) in their respective country and/or until the decision to close the study has been made by the sponsor.
PDS Implant with Ranibizumab 100 mg/mL
Will be administered as per the schedule described in individual arm
PDS Implant Cohort 7 (ex-US only)
Participants from Study WR42221 randomized to the Q36W arm, who will continue to be treated with refill-exchanges of ranibizumab 100 mg/mL Q36W. Participants will be in the study for a minimum of 144 weeks and may continue after Week 144 until the PDS has received Health Authority approval (or non-approval) in their respective country and/or until the decision to close the study has been made by the sponsor.
PDS Implant with Ranibizumab 100 mg/mL
Will be administered as per the schedule described in individual arm
Sub-study 1: PDS Implant
Participants will receive PDS implant using TPC on Day 1 followed by refill-exchanges of ranibizumab 100 mg/mL via the PDS Q24W.
PDS Implant with Ranibizumab 100 mg/mL
Will be administered as per the schedule described in individual arm
Sub-study 2: Cohort 1
Participants will undergo re-implantation with the updated PDS implant and receive 2 refill-exchanges of ranibizumab 100 mg/mL Q24W.
PDS Implant with Ranibizumab 100 mg/mL
Will be administered as per the schedule described in individual arm
Sub-study 2: Cohort 2a
Participants who received an updated PDS implant, have \< 24 weeks post-re-implantation follow-up and no refill exchange visit in the main study, will undergo two refill-exchange procedures with ranibizumab 100 mg/mL Q24W post main study re-implantation visit.
PDS Implant with Ranibizumab 100 mg/mL
Will be administered as per the schedule described in individual arm
Sub-study 2: Cohort 2b
Participants who received an updated PDS implant, have \< 48 weeks post-re-implantation follow-up and one refill exchange visit in the main study, will undergo one refill-exchange procedure with ranibizumab 100 mg/mL Q24W post main study re-implantation visit.
PDS Implant with Ranibizumab 100 mg/mL
Will be administered as per the schedule described in individual arm
PDS Implant Cohort 1 (US only)
Participants with PDS implant from Study GX28228 treated with refill-exchanges of 100 mg/mL ranibizumab Q24W. Participants will switch to an every 12 weeks (Q12W) visit schedule from Week 168 to Week 240.
Eligible participants from Study GX28228 will be enrolled upon completion of their final visit.
PDS Implant with Ranibizumab 100 mg/mL
Will be administered as per the schedule described in individual arm
PDS Implant Cohort 2 (US only)
Participants with PDS implant from Study GR40548 treated with refill-exchanges of 100 mg/mL ranibizumab Q24W. Participants will switch to an every 12 weeks (Q12W) visit schedule from Week 144 to Week 240.
Eligible participants from Study GR40548 will be enrolled upon completion of their final visit.
PDS Implant with Ranibizumab 100 mg/mL
Will be administered as per the schedule described in individual arm
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
PDS Implant with Ranibizumab 100 mg/mL
Will be administered as per the schedule described in individual arm
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Ability and willingness to undertake all scheduled visits and assessments
* For women of childbearing potential: agreement to remain abstinent or use contraceptive measures
\- For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures
Participants must meet the following ocular criteria for the study eye for substudy entry:
* Diagnosis of exudative nAMD within 2 years prior to the enrollment visit
* Previous treatment with at least two anti-VEGF ITV injections (e.g., ranibizumab, bevacizumab, or aflibercept) for nAMD per standard of care within 6 months prior to the enrollment visit
* Demonstrated response to prior anti-VEGF ITV treatment since diagnosis, as evidenced at enrollment by the following:
Overall decrease in nAMD disease activity detected on SD-OCT AND Stable or improved best-corrected visual acuity (BCVA)
* All subtypes of nAMD lesions are permissible (i.e., type I, type II, type III, or mixed forms per optical coherence tomography (OCT) classification) nAMD lesions at the time of diagnosis must involve the macula (6 mm diameter centered at the fovea).
* Sufficiently clear ocular media and adequate pupillary dilation to allow for analysis and grading by the central reading center of FP and SD-OCT images.
* Sufficiently clear ocular media and adequate pupillary dilation to allow for analysis and grading by central reading center
Exclusion Criteria
* History of other ocular diseases that give reasonable suspicion of a disease or condition that contraindicates the use of ranibizumab, that might affect interpretation of the results of the study or that renders the participant at high risk for treatment complications
* History of other diseases, metabolic dysfunction, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of ranibizumab or placement of the Implant and that might affect interpretation of the results of the study or that renders the participant at high risk of treatment complications
* Requirement for continuous use of any medications or treatments indicated in the "Prohibited Therapy"
Sub-study 1
* History of vitrectomy surgery, submacular surgery, or other surgical intervention for AMD
* Prior treatment with Visudyne, external-beam radiation therapy, or transpupillary thermotherapy
* Previous treatment with corticosteroid ITV injection
* Previous intraocular device implantation
* Previous laser (any type) used for AMD treatment
Either Eye
* Treatment with anti-VEGF agents other than ranibizumab within 1 month prior to the enrollment visit
* Prior participation in a clinical trial involving anti-VEGF drugs within 6 months prior to the enrollment visit, other than ranibizumab
CNV Lesion Charateristics Study Eye
* Subretinal hemorrhage that involves the center of the fovea, if the hemorrhage is greater than 0.5 disc area (1.27 mm2 ) in size at screening
* Subfoveal fibrosis or subfoveal atrophy
Either Eye
\- CNV due to other causes, such as ocular histoplasmosis, trauma, or pathologic myopia
Concurrent Ocular Conditions Study Eye
* Retinal pigment epithelial tear
* Any concurrent intraocular condition (e.g., cataract, glaucoma, diabetic retinopathy, or epiretinal membrane) that would either require surgical intervention during the study to prevent or treat visual loss that might result from that condition or affect interpretation of study results
* Active intraocular inflammation (grade trace or above)
* History of vitreous hemorrhage
* History of rhegmatogenous retinal detachment
* History of rhegmatogenous retinal tears or peripheral retinal breaks within 3 months prior to the enrollment visit
* Aphakia or absence of the posterior capsule
* Previous violation of the posterior capsule is also an exclusion criterion unless it occurred as a result of yttrium-aluminum garnet (YAG) laser posterior capsulotomy in association with prior, posterior chamber intraocular lens implantation.
* Spherical equivalent of the refractive error demonstrating more than 8 diopters of myopia
* Preoperative refractive error that exceeds 8 diopters of myopia, for participants who have undergone prior refractive or cataract surgery in the study eye
* Intraocular surgery (including cataract surgery) within 3 months preceding the enrollment visit
* Uncontrolled ocular hypertension or glaucoma and any such condition the investigator determines may require a glaucoma-filtering surgery during a patient's participation in the study
* History of glaucoma-filtering surgery, tube shunts, or microinvasive glaucoma surgery
* History of corneal transplant
* History of prior vitrectomy surgery and absence of posterior capsule
Either Eye
* History of idiopathic or autoimmune-associated uveitis
* Active infectious conjunctivitis, keratitis, scleritis, or endophthalmitis
Concurrent Systemic Conditions
* Inability to comply with study schedule or procedures as described in the study protocol
* Uncontrolled blood pressure
* History of stroke within the last 3 months prior to informed consent
* Uncontrolled atrial fibrillation within 3 months of informed consent
* History of myocardial infarction within the last 3 months prior to informed consent
* History of other disease, metabolic dysfunction, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of ranibizumab or placement of the implant and that might affect interpretation of the results of the study or renders the patient at high risk of treatment complications in the opinion of the investigator
* Current systemic treatment for a confirmed active systemic infection
* Use of any systemic anti-VEGF agents
* Chronic use of oral corticosteroids
* Active cancer within 12 months of enrollment
* Previous participation in any non-ocular (systemic) disease studies of investigational drugs within 1 month preceding the informed consent (excluding vitamins and minerals)
* Use of antimitotic or antimetabolite therapy within 30 days or 5 elimination half-lives of the enrollment visit
* History of albinism
* Pregnant or breastfeeding, or intending to become pregnant during the treatment period and for at least 28 days after the last ITV injection of ranibizumab or 1 year after the last implant refill-exchange of ranibizumab
Sub-study 2
Concurrent Ocular Conditions-Study Eye
* Any ocular condition that may render the patient at high risk for surgical or treatment complications
* Intraocular surgery (including cataract surgery) within 1 month preceding the enrollment visit
* Any use of medicated intraocular implants (other than the PDS implant), at any time prior to enrollment
* History of rhegmatogenous retinal tears or peripheral retinal breaks within 3 months prior to the enrollment visit
* Any concurrent ocular condition that would require surgical intervention during the study to prevent or treat visual loss
* Concurrent conjunctival, Tenon's capsule, and/or scleral condition in the supero-temporal quadrant of the eye (e.g., scarring, thinning, mass) that may affect the refill-exchange procedure of the PDS implant
* Ongoing ocular complications that might affect participant safety
Concurrent Ocular Conditions-Either Eye
* Suspected or active ocular or periocular infection
* Any history of uveitis
* Active blepharitis
Concurrent Systemic Conditions
* Recent history (in the last 3 months prior to enrollment) of other disease, other non-diabetic metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a condition that contraindicates the use of ranibizumab or surgical placement of the PDS implant; that might affect interpretation of the results of the study; or that renders the participant at high risk for treatment complications
* Active cancer within the last 12 months, except for appropriately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, or prostate cancer
* Current systemic treatment for a confirmed active systemic infection - Participation in an investigational trial that involves treatment with any drug or device (with the exception of vitamins and minerals or enrollment in the main study GR40549) within 6 months prior to enrollment.
* Use of antimitotic or antimetabolite therapy within 30 days or 5 elimination half-lives.
50 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hoffmann-La Roche
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Clinical Trials
Role: STUDY_DIRECTOR
Hoffmann-La Roche
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Retinal Research Institute, LLC
Phoenix, Arizona, United States
Arizona Retina and Vitreous Consultants
Phoenix, Arizona, United States
Barnet Dulaney Perkins Eye Center
Phoenix, Arizona, United States
Associated Retina Consultants
Phoenix, Arizona, United States
Retinal Consultants of Arizona
Phoenix, Arizona, United States
California Retina Consultants
Bakersfield, California, United States
Retina-Vitreous Associates Medical Group
Beverly Hills, California, United States
The Retina Partners
Encino, California, United States
Jacobs Retina center at the Shiley eye Institute UCSD
La Jolla, California, United States
Jules Stein Eye Institute/ UCLA
Los Angeles, California, United States
N CA Retina Vitreous Assoc
Mountain View, California, United States
Retina Consultants, San Diego
Poway, California, United States
Retinal Consultants Med Group
Sacramento, California, United States
West Coast Retina Medical Group
San Francisco, California, United States
UCSF
San Francisco, California, United States
Orange County Retina Med Group
Santa Ana, California, United States
California Retina Consultants
Santa Barbara, California, United States
Southwest Retina Consultants
Durango, Colorado, United States
Eye Center of Northern CO
Fort Collins, Colorado, United States
Colorado Retina Associates, PC
Lakewood, Colorado, United States
Retina Group of New England
Waterford, Connecticut, United States
Florida Eye Microsurgical Inst
Boynton Beach, Florida, United States
National Ophthalmic Research Institute
Fort Myers, Florida, United States
Florida Eye Associates
Melbourne, Florida, United States
Retina Care Specialists
Palm Beach Gardens, Florida, United States
Retina Specialty Institute
Pensacola, Florida, United States
Fort Lauderdale Eye Institute
Plantation, Florida, United States
Retina Vitreous Assoc of FL
St. Petersburg, Florida, United States
Southern Vitreoretinal Assoc
Tallahassee, Florida, United States
Retina Associates of Florida, LLC
Tampa, Florida, United States
Southeast Retina Center
Augusta, Georgia, United States
Georgia Retina PC
Marietta, Georgia, United States
Illinois Retina Associates
Joliet, Illinois, United States
University Retina and Macula Associates, PC
Oak Forest, Illinois, United States
Wolfe Eye Clinic
West Des Moines, Iowa, United States
Retina Associates
Lenexa, Kansas, United States
Retina Associates of Kentucky
Lexington, Kentucky, United States
Paducah Retinal Center
Paducah, Kentucky, United States
Maine Eye Center
Portland, Maine, United States
The Retina Care Center
Baltimore, Maryland, United States
Johns Hopkins Med
Baltimore, Maryland, United States
Retina Group of Washington
Chevy Chase, Maryland, United States
Retina Specialists
Towson, Maryland, United States
Ophthalmic Consultants of Boston
Boston, Massachusetts, United States
Foundation for Vision Research
Grand Rapids, Michigan, United States
Associated Retinal Consultants
Royal Oak, Michigan, United States
VitreoRetinal Surgery, PLLC.
Minneapolis, Minnesota, United States
Midwest Vision Research Foundation
Chesterfield, Missouri, United States
The Retina Institute - Chesterfield
St Louis, Missouri, United States
Sierra Eye Associates
Reno, Nevada, United States
Envision Ocular, LLC
Bloomfield, New Jersey, United States
Retina Associates of NJ
Teaneck, New Jersey, United States
University of New Mexico
Albuquerque, New Mexico, United States
Long Is. Vitreoretinal Consult
Great Neck, New York, United States
Retina Assoc of Western NY
Rochester, New York, United States
Ophthalmic Consultants of Long Island
Rockville Centre, New York, United States
Retina Vit Surgeons/Central NY
Syracuse, New York, United States
Char Eye Ear &Throat Assoc
Charlotte, North Carolina, United States
Cincinnati Eye Institute
Cincinnati, Ohio, United States
The Cleveland Clinic Foundation
Cleveland, Ohio, United States
OSU Eye Physicians & Surgeons
Columbus, Ohio, United States
Retina Vitreous Center
Edmond, Oklahoma, United States
Retina Northwest
Portland, Oregon, United States
Oregon HSU
Portland, Oregon, United States
Mid Atlantic Retina - Wills Eye Hospital
Philadelphia, Pennsylvania, United States
Palmetto Retina Center
Florence, South Carolina, United States
Palmetto Retina Center, LLC
West Columbia, South Carolina, United States
Charles Retina Institute
Germantown, Tennessee, United States
Tennessee Retina PC
Nashville, Tennessee, United States
Texas Retina Associates
Arlington, Texas, United States
Austin Retina Associates
Austin, Texas, United States
Austin Clinical Research LLC
Austin, Texas, United States
Retina Consultants of Texas
Bellaire, Texas, United States
Texas Retina Associates
Fort Worth, Texas, United States
Med Center Ophthalmology Assoc
San Antonio, Texas, United States
Retina Consultants of Texas
The Woodlands, Texas, United States
Retina Associates of Utah, PLLC
Salt Lake City, Utah, United States
Rocky Mountain Retina
Salt Lake City, Utah, United States
Wagner Kapoor Institute
Virginia Beach, Virginia, United States
Pacific Northwest Retina
Silverdale, Washington, United States
Spokane Eye Clinical Research
Spokane, Washington, United States
Oftalmos
Capital Federal, , Argentina
Centro Oftalmologico Dr. Charles S.A.
Ciudad Autonoma Buenos Aires, , Argentina
Grupo Laser Vision
Rosario, , Argentina
Eyeclinic Albury Wodonga
Albury, New South Wales, Australia
Eye and Retina Consultants
Hurstville, New South Wales, Australia
LKH-Univ.Klinikum Graz
Graz, , Austria
Medizinische Universitat Wien
Vienna, , Austria
UZ Leuven Gasthuisberg
Leuven, , Belgium
Botelho Hospital da Visao
Blumenau, Santa Catarina, Brazil
Retina Clinic
São Paulo, São Paulo, Brazil
Universidade Federal de Sao Paulo - UNIFESPX
São Paulo, São Paulo, Brazil
Instituto da Visao IPEPO
São Paulo, São Paulo, Brazil
Hosp de Olhos de Sorocaba
Sorocaba, São Paulo, Brazil
Centre Retine Gallien
Bordeaux, , France
Hopital de la croix rousse
Lyon, , France
Centre Paradis Monticelli
Marseille, , France
Hopital Lariboisiere
Paris, , France
Fondation Rothschild
Paris, , France
Universitatsklinikum Bonn
Bonn, , Germany
Universitatsklinikum Koln
Cologne, , Germany
Medizinische Universitat Lausitz ? Carl Thiem
Cottbus, , Germany
Universitätsklinikum Freiburg, Klinik für Augenheilkunde
Freiburg im Breisgau, , Germany
Universitatsklinikum Hamburg-Eppendorf
Hamburg, , Germany
Klinikum der Stadt Ludwigshafen am Rhein gGmbH
Ludwigshafen, , Germany
LMU Klinikum der Universitat, Augenklinik
München, , Germany
Augenabteilung am St. Franziskus-Hospital
Münster, , Germany
Universitatsklinikum Munster
Münster, , Germany
Knappschaftsklinikum Saar GmbH
Sulzbach, , Germany
Universitatsklinikum Tubingen
Tübingen, , Germany
Universitatsklinikum Ulm, Augenklinik und Poliklinik
Ulm, , Germany
Rambam Medical Center
Haifa, , Israel
Hadassah MC
Jerusalem, , Israel
Meir Medical Center
Kfar Saba, , Israel
Rabin MC
Petah Tikva, , Israel
Kaplan Medical Center
Rehovot, , Israel
Tel Aviv Sourasky MC
Tel Aviv, , Israel
Ospedale Clinicizzato SS Annunziata
Chieti, Abruzzo, Italy
Policlinico di Bari
Bari, Apulia, Italy
Azienda Ospedaliero Universitaria "Ospedali Riuniti" Trieste-Ospedale Maggiore
Trieste, Friuli Venezia Giulia, Italy
Policlinico Universitario Agostino Gemelli
Rome, Lazio, Italy
Fondazione G.B. Bietti Per Lo Studio E La Ricerca in Oftalmologia-Presidio Ospedaliero Britannico
Rome, Lazio, Italy
Fondazione Irccs Ca' Granda Ospedale Maggiore Policlinico-Clinica Regina Elena
Milan, Lombardy, Italy
Irccs Ospedale San Raffaele
Milan, Lombardy, Italy
Asst Fatebenefratelli Sacco
Milan, Lombardy, Italy
Azienda Ospedaliero Universitaria Ospedali Riuniti
Torrette - Ancona, The Marches, Italy
Azienda Ospedaliero-Universitaria Careggi
Florence, Tuscany, Italy
Azienda Ospedaliera di Perugia Ospedale S. Maria Della Misericordia
Perugia, Umbria, Italy
Ospedale Classificato Equiparato Sacro Cuore ? Don Calabria
Negrar - Verona, Veneto, Italy
A.O. Universitaria S. Maria Della Misericordia Di Udine
Udine, Veneto, Italy
Hospital Universitario de Bellvitge
L'Hospitalet de Llobregat, Barcelona, Spain
Hospital General de Catalunya
San Cugat Del Valles, Barcelona, Spain
Hospital Universitario Puerta de Hierro
Majadahonda, Madrid, Spain
Clinica Universitaria de Navarra
Pamplona, Navarre, Spain
Instituto Oftalmologico Fernandez Vega
Oviedo, Principality of Asturias, Spain
Oftalvist Valencia
Burjassot, Valencia, Spain
Centro de Oftalmologia Barraquer
Barcelona, , Spain
Institut de la Macula i la retina
Barcelona, , Spain
Hospital dos de maig
Barcelona, , Spain
Hospital Universitari Vall d'Hebron
Barcelona, , Spain
Hospital de la Arruzafa. Servicio de Oftalmologia
Córdoba, , Spain
Clinica Baviera
Madrid, , Spain
Universitatsspital Basel Augenklinik Klinik
Basel, , Switzerland
Inselspital Bern Ophthalmologische Klinik
Bern, , Switzerland
Vista Klinik Ophthalmologische Klinik
Binningen, , Switzerland
Fondation Asile Des Aveugles ? Jules Gonin Eye Hospital
Lausanne, , Switzerland
Stadtspital Triemli Ophthalmologische Klinik
Zurich, , Switzerland
Changhua Christian Hospital
Changhua, , Taiwan
Kaohsiung Medical University Chung-Ho Memorial Hospital
Kaohsiung City, , Taiwan
Taipei Veterans General Hospital
Taipei, , Taiwan
Chang Gung Medical Foundation - Linkou
Taoyuan District, , Taiwan
National Taiwan University Hospital
Zhongzheng Dist., , Taiwan
Hacettepe University Medical Faculty
Ankara, , Turkey (Türkiye)
Ankara Bilkent City Hospital
Ankara, , Turkey (Türkiye)
Ankara Etlik City Hospital
Ankara, , Turkey (Türkiye)
Beyoglu Goz Training and Research Hospital
Istanbul, , Turkey (Türkiye)
Kocaeli University Medical Faculty
Kocaeli, , Turkey (Türkiye)
Bristol Eye Hospital
Bristol, , United Kingdom
Royal Liverpool University Hospital
Liverpool, , United Kingdom
Moorfields Eye Hospital NHS Foundation Trust
London, , United Kingdom
Central Middlesex Hospital
London, , United Kingdom
Kings College Hospital NHS Foundation Trust
London, , United Kingdom
Royal Victoria Infirmary
Newcastle upon Tyne, , United Kingdom
Sunderland Eye Infirmary
Sunderland, , United Kingdom
Royal Wolverhampton hospital
Wolverhampton, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Reference Study ID Number: GR40549 https://forpatients.roche.com/
Role: CONTACT
References
Explore related publications, articles, or registry entries linked to this study.
Eichenbaum DA, Freeman WR, Chang MA, Brooks L, Chaudhry N, Dadgostar H, McCannel CA, Michels M, Mittra RA, Wolfe JD, Beindl VC, Jaycock P, Bobbala A, Gune S, Spicer G, Callaway N. Endophthalmitis in Eyes Treated with the Port Delivery System with Ranibizumab: Summary of Cases during Clinical Trial Development. Ophthalmol Retina. 2025 Feb;9(2):127-143. doi: 10.1016/j.oret.2024.08.005. Epub 2024 Aug 16.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2020-004427-16
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
2023-507131-38-00
Identifier Type: CTIS
Identifier Source: secondary_id
GR40549
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.